352431-47-1Relevant articles and documents
DEUTERATED ANALOGS OF ACETYL-LEUCINE
-
Paragraph 0530; 0532, (2020/07/05)
The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined as set forth in the specification, and the deuterium enrichment of any one or more of R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is about 15% or more. The present disclosure also provides compounds having Formula I for use to treat or delay the progression of a lysosomal storage disorder or a neurodegenerative disease in a subject, provide neuroprotection in a subject having a lysosomal disorder, treat or prevent a migraine, and the symptoms associated therewith, in a subject, or improve mobility and/or cognitive function in a subject.
Boric acid compound, borate compound and their preparation methods and application
-
Paragraph 0188; 0189, (2018/12/02)
The invention provides a boric acid compound and a borate compound shown as formula I and formula II which are shown in the description, and their preparation methods, application and pharmaceutical compositions. The boric acid compound and the borate compound can inhibit proteasome and are suitable for treating multiple myeloma.